These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 21068436)

  • 1. Improving academic leadership and oversight in large industry-sponsored clinical trials: the ARO-CRO model.
    Goldenberg NA; Spyropoulos AC; Halperin JL; Kessler CM; Schulman S; Turpie AG; Skene AM; Cutler NR; Hiatt WR;
    Blood; 2011 Feb; 117(7):2089-92. PubMed ID: 21068436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. American Society of Clinical Oncology policy statement: oversight of clinical research.
    American Society of Clinical Oncology
    J Clin Oncol; 2003 Jun; 21(12):2377-86. PubMed ID: 12721281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical trials integrity: a CRO perspective.
    Beach JE
    Account Res; 2001; 8(3):245-60. PubMed ID: 12481762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oversight of financial conflicts of interest in commercially sponsored research in academic and nonacademic settings.
    Weinfurt KP; Hall MA; Hardy NC; Friedman JY; Schulman KA; Sugarman J
    J Gen Intern Med; 2010 May; 25(5):460-4. PubMed ID: 20186498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conflicts of interest in research involving human beings.
    Greco D; Diniz NM
    J Int Bioethique; 2008; 19(1-2):143-54, 202-3. PubMed ID: 18664007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conflicts of interest in data monitoring of industry versus publicly financed clinical trials.
    Lachin JM
    Stat Med; 2004 May; 23(10):1519-21. PubMed ID: 15122730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current practice and perspectives in CRO oversight based on a survey performed among members of the German Association of Research-Based Pharmaceutical Companies (vfa).
    Hennig M; Hundt F; Busta S; Mikus S; Sanden PH; Sörgel A; Ruppert T
    Ger Med Sci; 2017; 15():Doc02. PubMed ID: 28163667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A call to rethink the necessity of and challenges facing academic research organizations in the new era of drug innovation in China.
    Huang H; Jiang N; Chen W; Tang Y; Li N
    Drug Discov Today; 2024 Apr; 29(4):103925. PubMed ID: 38403155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ethics and industry-sponsored research.
    Kuebler C; Nimmo WS; von R; Gillings D; Morgan AT; Kendle C; Covington PS
    CMAJ; 2002 Mar; 166(5):579-80; author reply 582. PubMed ID: 11898930
    [No Abstract]   [Full Text] [Related]  

  • 10. A third trial oversight committee: Functions, benefits and issues.
    Lane JA; Gamble C; Cragg WJ; Tembo D; Sydes MR
    Clin Trials; 2020 Feb; 17(1):106-112. PubMed ID: 31665920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recommendations for data monitoring committees from the Clinical Trials Transformation Initiative.
    Calis KA; Archdeacon P; Bain R; DeMets D; Donohue M; Elzarrad MK; Forrest A; McEachern J; Pencina MJ; Perlmutter J; Lewis RJ
    Clin Trials; 2017 Aug; 14(4):342-348. PubMed ID: 28503947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 'We all want to succeed, but we've also got to be realistic about what is happening': an ethnographic study of relationships in trial oversight and their impact.
    Daykin A; Selman LE; Cramer H; McCann S; Shorter GW; Sydes MR; Gamble C; Macefield R; Lane JA; Shaw A
    Trials; 2017 Dec; 18(1):612. PubMed ID: 29273060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploring the role and function of trial steering committees: results of an expert panel meeting.
    Harman NL; Conroy EJ; Lewis SC; Murray G; Norrie J; Sydes MR; Lane JA; Altman DG; Baigent C; Bliss JM; Campbell MK; Elbourne D; Evans S; Sandercock P; Gamble C
    Trials; 2015 Dec; 16():597. PubMed ID: 26715378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Understanding the functions and operations of data monitoring committees: Survey and focus group findings.
    Calis KA; Archdeacon P; Bain RP; Forrest A; Perlmutter J; DeMets DL
    Clin Trials; 2017 Feb; 14(1):59-66. PubMed ID: 27885056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Data monitoring and interim analyses in the pharmaceutical industry: ethical and logistical considerations.
    Rockhold FW; Enas GG
    Stat Med; 1993 Mar; 12(5-6):471-9. PubMed ID: 8493425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical investigators and the pharmaceutical industry.
    Newman TJ
    N Engl J Med; 2000 Aug; 343(7):510-1. PubMed ID: 10950675
    [No Abstract]   [Full Text] [Related]  

  • 17. Commercializing clinical trials--risks and benefits of the CRO boom.
    Shuchman M
    N Engl J Med; 2007 Oct; 357(14):1365-8. PubMed ID: 17914036
    [No Abstract]   [Full Text] [Related]  

  • 18. Reporting mortality findings in trials of rofecoxib for Alzheimer disease or cognitive impairment: a case study based on documents from rofecoxib litigation.
    Psaty BM; Kronmal RA
    JAMA; 2008 Apr; 299(15):1813-7. PubMed ID: 18413875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gag clauses in clinical-trial agreements.
    Steinbrook R
    N Engl J Med; 2005 May; 352(21):2160-2. PubMed ID: 15917381
    [No Abstract]   [Full Text] [Related]  

  • 20. Ethical management of conflict of interest: proposed standards for academic surgical societies.
    Minter RM; Angelos P; Coimbra R; Dale P; de Vera ME; Hardacre J; Hawkins W; Kirkwood K; Matthews JB; McLoughlin J; Peralta E; Schmidt M; Zhou W; Schwarze ML
    J Am Coll Surg; 2011 Nov; 213(5):677-82. PubMed ID: 21880513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.